FT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., today announced that the company has acquired from Gilead Sciences, Inc. an exclusive North American license to develop and commercialize Gilead’s investigational molecule, GS 9219, for use in animal cancer. GS 9219 is an anti-proliferative agent that preferentially targets lymphoid cells and works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
